Neurophysiological effects of rTMS

Citation for published version (APA):

Document status and date:
Published: 01/09/2021

DOI:
10.1016/j.clinph.2021.06.010

Document Version:
Publisher's PDF, also known as Version of record

Document license:
Taverne

Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher’s website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.

Download date: 03 Nov. 2023
Transcranial Magnetic Stimulation (TMS) as a treatment for drug-resistant major depressive disorder (MDD) has been around since the first pioneering reports by Mark George (George et al., 1995) and Alvaro Pascual-Leone (Pascual-Leone et al., 1996) in the mid 1990s. However, the exact working mechanism of rTMS remains elusive as of this day. The initial conceptualizations revolved around the earlier idea of ‘left prefrontal dysfunction’. Our current understanding of brain function in MDD has moved away from a locationistic view to a distributed network function view, attributing important roles to the Default Mode and Central Executive networks for a role in MDD, with rTMS thought to modulate functional connectivity within and between these networks with a key role for the subgenual anterior cingular cortex (ACC) (Liston et al., 2014).

TMS as a technique has not only brought us an innovative treatment modality, but also a valuable technique that can ‘ping the brain’ to better understand brain function, and possibly a biomarker, also referred to as TMS Evoked Potentials or TEP. TEPs are thought to index propagation of the TMS pulse as well as transynaptic cortical effects. However, due to the nature of the relatively loud TMS pulses and somatosensory effects (potentially eliciting evoked potentials with auditory and somatosensory origin), caution has been warranted in attributing all TEP components to be evoked potentials with auditory and somatosensory origin, rather than TMS effects. Nonetheless, the results from Voineskos and colleagues (Voineskos et al., 2021) is restricted to the left DLPFC further demonstrated an overall effect of TEP amplitude, not associated with HAMD symptom change, but with baseline TEP amplitude being highly predictive of post-treatment resolution of suicidality with sensitivity and specificity of 87.5% and 77.8%, respectively.

The N100 has often been implicated in studies on MDD and antidepressant response, for instance when recorded in an auditory oddball paradigm where larger N100 amplitudes (more negative) were found to be associated with better clinical response to several antidepressants (Spronk et al., 2008), and worse response to venlafaxine for males in the large iSPOT-D trial (van Dinteren et al., 2015). Furthermore, N100 is also an important component of the Loudness Dependent Auditory Evoked Potential (LDAEP) that has been shown to index serotonergic and possibly glutamatergic innervation (Kenemans and Kähkönen, 2010), and has received interest as a diagnostic and predictive biomarker in MDD. Using an auditory oddball paradigm instead of TMS-EEG, we also reported a decreased N100 amplitude from pre- to post-rTMS in MDD, that was specifically confined to the left pre-frontal cortex (Spronk et al., 2008), conceptually in line with the TEP-N100 results as reported by Voineskos and colleagues (Voineskos et al., 2021). This raises the question, how specific the N100 TEP as reported by Voineskos and colleagues (Voineskos et al., 2021) is to transcranial stimulation, auditory stimulation, a combination thereof, or simply an overlap in neural underpinnings. This will require further elucidation, since, if similar associations could be obtained using an auditory oddball paradigm, this might be preferred over TMS-EEG, for ease of use and higher yield of good quality signal which is crucial for clinical applications (e.g., only for 30/66 people TEPs could be determined due to excessive artifacts, inadequately low trial numbers with TMS pulses and incomplete recordings). Future studies might collect both TEP as well as auditory oddball ERP data within the same MDD patients to shed further light on similarities and differences and unique signal between both approaches to further uncover the added value of both techniques. Nonetheless, the results from Voineskos and colleagues (Voineskos et al., 2021) add to an existing literature that
posits an important role for the N100 ERP/TEP component in tracking and predicting antidepressant response. This suggests that the N100 might be more relevant than other commonly investigated ERP components such as the P300 that yielded relatively little success and inconsistent findings (van Dinteren et al., 2015).

The finding from Voineskos and colleagues (Voineskos et al., 2021) regarding the more focal left DLPFC TEP amplitude so strongly predicting suicidality response to rTMS treatment are novel and intriguing. Clinical implications for such a predictive marker would be immense (and literally life-saving), since it could help prioritize rTMS treatment for specific high-risk patient groups that present with that specific marker. However, that finding calls for replication in an independent sample and extension to other antidepressant treatments to ensure its potential as a clinically actionable biomarker, something we’ve recently been unsuccessful with for a suicidality EEG-risk marker (Krepel et al., 2021). If replicated, this finding would bring back old memories of the original more focal ‘left prefrontal dysfunction’ hypothesis, however, now more specifically as a target for remission of suicidality after rTMS, potentially in line with suicidality fulfilling a more transdiagnostic role in psychiatry.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References


Martijn Arns a, b, c;* and Helena Voetterl a, b

a Research Institute Brainclinics, Brainclinics Foundation, Nijmegen, the Netherlands

b Department of Psychiatry, Amsterdam UMC, University of Amsterdam, Location AMC, Amsterdam Neuroscience, the Netherlands

c Department of Cognitive Neuroscience, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands

* Corresponding author at: Research Institute Brainclinics, Brainclinics Foundation, Bijleveldsingel 34, 6524 AD Nijmegen, the Netherlands.

E-mail address: martijn@brainclinics.com (M. Arns)

Accepted 25 June 2021

Available online 30 June 2021